Topline data from MISSION Phase 2 trial of zetomipzomib for the treatment of lupus nephritis expected in June 2022, consistent...
Reports
-- First patient dosed in the Phase 1 clinical trial evaluating ACLX-001 utilizing groundbreaking ARC-SparX technology in relapsed or refractory...
Motus GI Holdings, Inc.Pure-Vu EVS approved for use at 11 hospitals since product launch commenced in March 2022; with strong...
GPH101 for sickle cell disease granted U.S. FDA Fast Track Designation; dosing of first patient in Phase 1/2 CEDAR clinical...
NeuBase Therapeutics, Inc.Investigational New Drug (IND)-enabling studies continue to generate promising data that support further development of the company’s lead...
Conference call begins at 2:00 p.m. Pacific time todayPLEASANTON, Calif., May 12, 2022 /PRNewswire/ -- Today, Movano Inc. (NASDAQ: MOVE),...
